Carbon Ion Radiotherapy for Recurrent Pancreatic Cancer Post Surgery

Status Recruiting

Clinical Trial Summary

The aim of this study is to evaluate the toxicity and tolerance of carbon ion radiotherapy for recurrent pancreatic carcinoma post surgery

Clinical Trial Description

The carbon dose of 67.5 Gy equivalent in 15 fractions was delivered to clinical target volume (CTV). The dose limiting toxicity (DLT) was defined as CTCAE grade 3 or higher of non-hematological toxicity (G3). The acute and late toxicities, overall survival (OS), progression-free survival (PFS), local progression-free survival (LPFS) and distant metastasis-free survival (DMFS) were the endpoints. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT05830019
Study type	Interventional
Source	Shanghai Proton and Heavy Ion Center
Contact	Xin Cai, Dr.
Phone	+862138296666
Email	xin.cai@sphic.org.cn
Status	Recruiting
Phase	N/A
Start date	June 1, 2021
Completion date	December 31, 2024

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT05497531` - Pilot Comparing ctDNA IDV vs. SPV Sample in Pts Undergoing Biopsies for Hepatobiliary and Pancreatic Cancers	N/A
Recruiting	`NCT05237193` - A Prospective Study of UCAD for Diagnosing Benign or Malignant Biliary Obstruction and Follow-up
Active, not recruiting	`NCT04602026` - The RIOT Trial: Re-Defining Frailty and Improving Outcomes With Prehabilitation for Pancreatic, Liver, or Gastric Cancer	N/A
Recruiting	`NCT05613465` - Adjuvant Chemotherapy Plus Codonopsis Pilosula Nnannf /Placebo	N/A
Completed	`NCT03645148` - Clinical Study of a Personalized Neoantigen Cancer Vaccine in Treating Patients With Advanced Pancreatic Cancer	Phase 1
Recruiting	`NCT02587689` - Phase I/II Study of Anti-Mucin1 (MUC1) CAR T Cells for Patients With MUC1+ Advanced Refractory Solid Tumor	Phase 1/Phase 2
Active, not recruiting	`NCT02676349` - Neoadjuvant mFolfirinox With or Without Preoperative Concomitant Chemoradiotherapy in Patients With Borderline Resectable Pancreatic Carcinoma (PANDAS-PRODIGE 44)	Phase 2
Active, not recruiting	`NCT03267524` - Walking for Recovery From Surgery in Improving Quality of Life in Older Adults With Lung or Gastrointestinal Cancer and Their Family Caregivers	N/A
Recruiting	`NCT04147494` - Experimental PET Imaging Scans Before Cancer Surgery to Study the Amount of PET Tracer Accumulated in Normal and Cancer Tissues	Early Phase 1
Recruiting	`NCT05642962` - Pancrelipase in People With Pancreatic Ductal Adenocarcinoma (PDAC)	Phase 1/Phase 2
Active, not recruiting	`NCT03164486` - First-in-Human Positron Emission Tomography Study Using the 18F-αvβ6-Binding-Peptide	Early Phase 1
Active, not recruiting	`NCT02009449` - A Phase 1 Study of Pegilodecakin (LY3500518) in Participants With Advanced Solid Tumors	Phase 1
Terminated	`NCT03137706` - Characterization of Mechanical Tissue Properties in Patients With Pancreatic, Liver, or Colon Cancer
Not yet recruiting	`NCT06080854` - AG Combined With Immunotherapy and SBRT in Patients With Potentially Resectable Pancreatic Cancer	Phase 2
Completed	`NCT03962478` - Combined Stent Insertion and HIFU Ablation for Pancreatic Carcinoma With Biliary Obstruction	N/A
Completed	`NCT03849469` - A Study of XmAb®22841 Monotherapy & in Combination w/ Pembrolizumab in Subjects w/ Selected Advanced Solid Tumors	Phase 1
Terminated	`NCT00907166` - A Phase I/II Open-Label Dose-Escalation Clinical Trial of CPI-613 in Combination With Gemcitabine in Cancer Patients	Phase 1/Phase 2
Active, not recruiting	`NCT03752398` - A Study of XmAb®23104 in Subjects With Selected Advanced Solid Tumors (DUET-3)	Phase 1
Completed	`NCT03949933` - Proton and Carbon Ion Radiotherapy for Locally Advanced Pancreatic Cancer	N/A
Recruiting	`NCT03711890` - Ultra-High Resolution Optical Coherence Tomography in Detecting Micrometer Sized Early Stage Pancreatic Cancer in Participants With Pancreatic Cancer	N/A